Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777759 | 0.80 | CHRM5 (0.42) | — | |
| SCHEMBL13443083 | 0.77 | KCNA5 (0.47) | KCNA5SYKCHRNB2CHRNA4NOTUM | |
| SCHEMBL3409401 | 0.75 | KCNA5 (0.49) | KCNA5CHRNB2CHRNA4GRM5CHRNA7 | |
| SCHEMBL4777939 | 0.73 | CYP2D6 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4024971 | 0.73 | KCNA5 (0.47) | KCNA5CHRNB2CHRNA4GRM5CHRNA7 | |
| SCHEMBL27549059 | 0.72 | KCNA5 (0.51) | KCNA5CHRNB2CHRNA4NOTUMGRM5 | |
| SCHEMBL5075470 | 0.70 | KCNA5 (0.50) | KCNA5CHRNB2CHRNA4NOTUMGRM5 | |
| SCHEMBL5035544 | 0.70 | KCNA5 (0.47) | KCNA5SYKCHRNB2CHRNA4NOTUM | |
| SCHEMBL182698 | 0.69 | — | — | |
| SCHEMBL2128199 | 0.68 | CYP2A6 (0.47) | KCNA5SYKCHRNB2CHRNA4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | KCNA5 1686/4885SYK 3193/4885MAP3K8 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.